Vascular surgery

Cardiovascular Systems, Inc. to Participate at BofA Securities 2021 Health Care Conference

Retrieved on: 
Tuesday, April 27, 2021
Health, Surgery, Cardiology, Medical devices, Interventional radiology, Atherectomy, Vascular surgery

b"Cardiovascular Systems, Inc. (CSI\xc2\xae) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the BofA Securities 2021 Health Care Conference on May 11th.

Key Points: 
  • b"Cardiovascular Systems, Inc. (CSI\xc2\xae) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the BofA Securities 2021 Health Care Conference on May 11th.
  • A webcast of the presentation will be made available on CSI's website.\nCardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.
  • The company\xe2\x80\x99s orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.
  • For additional information, please visit www.csi360.com and connect on Twitter @csi360.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210427005112/en/\n"

Modern Vascular Brings Technology and Innovation to Reduce Unnecessary Limb Loss in Indiana

Retrieved on: 
Monday, April 26, 2021
Medical specialties, Medicine, Clinical medicine, Surgical specialties, Peripheral artery disease, Medical imaging, Interventional radiology, Amputation, Angiography, Radiology, Vascular surgery

Dr. Borenstein has been practicing Interventional and Vascular Radiology for over 25 years, most recently in Northern Indiana.

Key Points: 
  • Dr. Borenstein has been practicing Interventional and Vascular Radiology for over 25 years, most recently in Northern Indiana.
  • Modern Vascular clinics specialize in the treatment of peripheral artery disease (PAD) through below-the-knee and below-the-ankle and pedal endovascular arterial reconstruction.
  • Modern Vascular procedures are also an important step in avoiding future limb amputation and extending life expectancy in diabetic, cardiovascular, and peripheral artery disease patients.
  • Modern Vascular now operates and manages fourteen clinics across AZ, CO, IN, MS, NM, TX, VA. For more information, visit www.ModernVascular.com .

Global Atherectomy Devices Market Analysis 2021-2027: Product (Laser Atherectomy, Mechanical Atherectomy), Indication (Coronary, Peripheral) - ResearchAndMarkets.com

Retrieved on: 
Monday, April 26, 2021
Medical devices, Health, Interventional radiology, Atherectomy, Vascular surgery, Interventional cardiology, Cardiology

b'The "Global Atherectomy Devices Market Analysis - 2021-2027 - MedCore - Segmented by: Product (Laser Atherectomy, Mechanical Atherectomy), Indication (Coronary, Peripheral)" report has been added to ResearchAndMarkets.com\'s offering.\nThe global peripheral atherectomy devices market size is estimated to increase over the forecast period to exceed $1.1 billion in 2027.\nOn the other hand, the global coronary atherectomy devices market size is expected to reach over $947.4 million in 2027.\nFor the coronary atherectomy devices, the largest global market was the North American region.

Key Points: 
  • b'The "Global Atherectomy Devices Market Analysis - 2021-2027 - MedCore - Segmented by: Product (Laser Atherectomy, Mechanical Atherectomy), Indication (Coronary, Peripheral)" report has been added to ResearchAndMarkets.com\'s offering.\nThe global peripheral atherectomy devices market size is estimated to increase over the forecast period to exceed $1.1 billion in 2027.\nOn the other hand, the global coronary atherectomy devices market size is expected to reach over $947.4 million in 2027.\nFor the coronary atherectomy devices, the largest global market was the North American region.
  • Within this region, the mechanical atherectomy devices are currently used for the majority of atherectomy procedures and account for the majority of the total units sold.
  • However, competitive pricing pressure and bundling of interventional cardiology devices has led to average selling price depreciation and limited the market value growth in the mechanical atherectomy segment.\nSimilar to the coronary atherectomy market, the largest market for the peripheral devices was the North American region.
  • Because the peripheral atherectomy devices operate on the same principles as coronary ones, the mechanical atherectomy segment also accounted for the vast majority of the total market within this region.

InspireMD Provides Corporate Update for Shareholders

Retrieved on: 
Monday, April 19, 2021
Medical specialties, Neurosurgery, Vascular surgery, Vascular diseases, Carotid stenting, Clinical medicine, Carotid artery, Medicine

Our business model, superior technology platform harnessed by our proprietary MicroNet embolic protection system and timing of the growth in carotid stenting have laid the foundation necessary for CGuard EPS to become a market leader in the prevention of stroke caused by carotid artery disease.

Key Points: 
  • Our business model, superior technology platform harnessed by our proprietary MicroNet embolic protection system and timing of the growth in carotid stenting have laid the foundation necessary for CGuard EPS to become a market leader in the prevention of stroke caused by carotid artery disease.
  • We believe that moving to the Nasdaq Capital Market is a strategically sound approach that places us in the company of our peers and allows for improved visibility in the market.
  • Investors and security holders are urged to read these documents free of charge on the SEC\xe2\x80\x99s web site at http://www.sec.gov.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\n'

Worldwide Intracranial Aneurysm Industry to 2025 - Featuring Medtronic, B. Braun and Penumbra Among Others

Retrieved on: 
Tuesday, April 20, 2021
Medical specialties, Neurosurgery, Angiology, Cardiovascular system, Vascular diseases, Interventional radiology, Aneurysm, Gross pathology, Endovascular coiling, Surgery, Vascular surgery, Intracranial aneurysm

Amongst all, the endovascular coiling segment holds the highest market share.\nBy Condition, the market is classified as an unruptured aneurysm and Ruptured aneurysm.

Key Points: 
  • Amongst all, the endovascular coiling segment holds the highest market share.\nBy Condition, the market is classified as an unruptured aneurysm and Ruptured aneurysm.
  • Amongst all, the ruptured aneurysm segment holds the highest market share.\nBy Treatment Type, the market is classified as Medication and Surgery.
  • Amongst all, the surgery segment holds the highest market share.\nBy End-user, the market is classified as Hospital & Clinics, Diagnostic Centers, and others.
  • Amongst all, the hospital segment holds the highest market share.\nBy Geography, North America is projected to lead the market.\n1.

The Society for Vascular Surgery Partners with the Academy for Surgical Coaching to Take Wellness Support to the Next Level

Retrieved on: 
Wednesday, April 7, 2021
Vascular surgery, Surgery, Surgeon

Rosemont, Ill., April 07, 2021 (GLOBE NEWSWIRE) -- The Society for Vascular Surgery (SVS) and the Academy for Surgical Coaching today announced a partnership to develop a first-of-its-kind coaching program that strengthens wellness support for vascular surgeons.

Key Points: 
  • Rosemont, Ill., April 07, 2021 (GLOBE NEWSWIRE) -- The Society for Vascular Surgery (SVS) and the Academy for Surgical Coaching today announced a partnership to develop a first-of-its-kind coaching program that strengthens wellness support for vascular surgeons.
  • With this new program, customized to vascular surgery, SVS aims to address the triggers of burnout and provide wellness support through coaching intervention.
  • The Academy for Surgical Coaching trains surgeons to become Surgical Coaches, pairs surgeons with Surgical Coaches, and manages coaching programs.
  • The Academy for Surgical Coaching has trained over 130 Surgical Coaches and conducted over 300 hours of surgical coaching.

CryoLife to Participate in 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 7, 2021
CryoLife, Vascular surgery, Fireside chats, 20th century in the United States, The United States

ATLANTA, April 7, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021.

Key Points: 
  • ATLANTA, April 7, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021.
  • The Company's virtual fireside chat is scheduled to begin at 8:45 a.m.
  • A live webcast of the virtual fireside chat will be accessible through CryoLife's website, www.cryolife.com , on the Investor Relations page.
  • For additional information about CryoLife, visit our website, www.cryolife.com .

LeMaitre to Present at the Needham Virtual Healthcare Conference

Retrieved on: 
Monday, April 5, 2021
LeMaitre Vascular, Lemaitre, Vascular surgery

BURLINGTON, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc.(Nasdaq:LMAT) announced today thatJJ Pellegrino, Chief Financial Officer, will present atthe 20th Annual Needham Virtual Healthcare Conference onMonday, April 12, 2021, at9:30 AM EDT.

Key Points: 
  • BURLINGTON, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc.(Nasdaq:LMAT) announced today thatJJ Pellegrino, Chief Financial Officer, will present atthe 20th Annual Needham Virtual Healthcare Conference onMonday, April 12, 2021, at9:30 AM EDT.
  • LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide.
  • The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.
  • Additional information can be found at www.lemaitre.com .

Physicians In The U.S. Begin Commercial Use Of The GORE® EXCLUDER® Conformable AAA Endoprosthesis With ACTIVE CONTROL System

Retrieved on: 
Tuesday, March 30, 2021
Medical specialties, Angiology, Vascular surgery, Cardiovascular system, Aortic aneurysm, Abdominal aortic aneurysm, Aneurysm, Gore, Clinical trial

FLAGSTAFF,Ariz., March 30, 2021 /PRNewswire/ --Today, W.L.Gore& Associates, Inc. (Gore) announces the first use of the FDA approved GORE EXCLUDERConformable AAA Endoprothesis with ACTIVE CONTROL System in cases outside of clinical trials.

Key Points: 
  • FLAGSTAFF,Ariz., March 30, 2021 /PRNewswire/ --Today, W.L.Gore& Associates, Inc. (Gore) announces the first use of the FDA approved GORE EXCLUDERConformable AAA Endoprothesis with ACTIVE CONTROL System in cases outside of clinical trials.
  • "Gore has combined a novel stent design, device conformability and an enhanced delivery system to give physicians even more control when we need it most."
  • For more information on the GORE EXCLUDER Conformable AAA Endoprosthesis and the GORE EXCLUDER Device family, visit goremedical.com .
  • Assessment of the GORE EXCLUDER Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms.

SANUWAVE Health Announces Expansion of Ametus Group Distribution Partnership

Retrieved on: 
Tuesday, March 30, 2021
Medicine, Podiatry, Clinical medicine, Surgery, Vascular surgery, Chronic wound, Plastic surgery, Salesforce, Health care, Podiatrist

The SANUWAVE Ametus partnership increases the commercial footprint in areas with little to no representation, increasing feet on the street to continue to drive the ENERGY FIRST portfolio.

Key Points: 
  • The SANUWAVE Ametus partnership increases the commercial footprint in areas with little to no representation, increasing feet on the street to continue to drive the ENERGY FIRST portfolio.
  • We are excited to bring on a seasoned wound care salesforce with established relationships and a solid customer base, stated Jack Schlechtweg, Chief Revenue Officer of SANUWAVE Health.
  • The Ametus Group is extremely excited to be partnering with SANUWAVE to commercialize the innovative and clinically proven portfolio of energy-based and biological technologies to treat the growing chronic wound care population, stated Ametus Group co-founders and Managing Partners Randy Seeliger and Mark Will.
  • The Ametus Group specializes in consultative sales distribution in the advanced wound care, podiatric surgery, vascular surgery, and plastic surgery.